NeuroBo Pharmaceuticals, Inc. Common Stock
NRBO
NRBO: NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused primarily on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of nonalcoholic steatohepatitis (NASH), obesity, and type 2 diabetes (T2D): DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
moreShow NRBO Financials
Recent trades of NRBO by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by NRBO's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Composition containing mixed extract of mulberry and Mar. 16, 2021
-
Patent Title: Composition containing Dec. 15, 2020
-
Patent Title: Methods of reducing risk of cardiovascular disease Jul. 14, 2020
-
Patent Title: Composition containing mixed extract of mulberry and Mar. 17, 2020
Federal grants, loans, and purchases
Followers on NRBO's company Twitter account
Number of mentions of NRBO in WallStreetBets Daily Discussion
Recent insights relating to NRBO
Recent picks made for NRBO stock on CNBC
ETFs with the largest estimated holdings in NRBO
Flights by private jets registered to NRBO